Medifast (MED) Cash & Current Investments (2010 - 2026)

Medifast has reported Cash & Current Investments for 17 years, with the latest figure at $168.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 2.64% year-over-year to $168.9 million; the trailing twelve-month figure through Mar 2026 stood at $168.9 million (up 2.64% YoY), and the FY2025 full-year result was $167.3 million, up 3.04% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $168.9 million, up from $167.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $173.5 million in Q3 2025, with the low at $61.1 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $141.7 million across 5 years, with a median of $157.8 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 69.07% — and 2023, when it surged 141.37%.
• Medifast's Cash & Current Investments stood at $87.7 million in 2022, then jumped by 71.1% to $150.0 million in 2023, then advanced by 8.2% to $162.3 million in 2024, then grew by 3.04% to $167.3 million in 2025, then rose by 1.0% to $168.9 million in 2026.
• The last three Cash & Current Investments figures came in at $168.9 million (Q1 2026), $167.3 million (Q4 2025), and $173.5 million (Q3 2025), per Business Quant data.